Dr Reddys Laboratories launches Albendazole Tablets in U.S. market

Dr. Reddy's Laboratories announced the launch of Albendazole Tablets, USP, a therapeutic equivalent generic version of Albenza Tablets, 200 mg, approved by the U.S. Food and Drug Administration (USFDA).

The Albenza brand and generic had U.S. sales of approximately $27 million MAT for the most recent twelve months ending in November 2020 according to IQVIA Health.

Dr. Reddy's Albendazole Tablets, USP are available in 200 mg tablets in bottle count sizes of two.

Albenza is a trademark of GlaxoSmithKline.

Powered by Capital Market - Live News